Participants
Participants could both be referred to by healthcare practitioners or self-refer in to the trial. The trial inclusion criteria were adults 18 years or older, with self-reported pain for three months or more who were able to take part in group discussions in Norwegian. In addition, they agreed to accept randomisation to one of the trial interventions after a full explanation of the trial. The exclusion criteria included an inability to participate in a low-impact physical activity for one hour, pain arising from malignant diseases, and lacking the capacity to consent.
Recruitment for the trial was communicated through posters and information leaflets distributed to general practitioners, physiotherapists, relevant departments at the hospital, Norwegian Labour and Welfare Administration offices and other relevant organisations in the municipality. Advertisements were placed in local newspapers, websites, social media and email invitations to patient organisations. Those interested in participating were encouraged to contact the first author by either phone or email. The first author checked the eligibility criteria, provided additional information about the trial and scheduled appointments for baseline assessments.
Procedure, randomisation and blinding
Following the baseline assessments, the participants were consecutively, individually and randomly allocated to one of the two trial arms using a computer-based Internet trial service provided by a third party (Unit for Applied Clinical Research at the Norwegian University of Science and Technology, NTNU). A 1:1 ratio and a stratification for gender were used. Those involved in the trial were blinded to the block sizes.
Immediately after the randomisation, the participants were informed of their allocation by either phone or by an email from the first author. The research assistant who conducted the physical ability test at the follow-up appointments was blinded to allocations; otherwise, it was an open study, including the outcome assessments.
The outcomes were assessed at the baseline, and at three, six and twelve months after the completion of the intervention. The assessments after six and twelve months are reported here. At the baseline, the self-administrated questionnaire was completed with the first author available for questions. For the follow-up appointments, the questionnaires were collected when the participants met for the 30-s Chair to Stand Test.
The self-management course
The chronic pain self-management course, developed locally by the HLC staff in cooperation with a patient organisation representative, aimed to increase the participants’ knowledge, skills and confidence in managing everyday life with chronic pain [
27]. The course was developed in accordance with the characteristics of self-management interventions [
14], recommendations in the literature (e.g., [
31‐
35]), the guidelines of the HLC [
28] and personal experiences working with behavioural changes and the self-management of chronic conditions. Hence, the course addressed central self-management skills such as goal setting, action planning, and problem solving, and focussed on empowering the participants to play an active role in their healthcare. The chronic pain self-management course included education introducing cognitive and behavioural strategies for pain management [
31‐
33,
35], pain theory, discussions of barriers in everyday life due to chronic pain, and techniques to deal with fatigue, poor sleep, frustration and isolation. For the movement exercises concluding each session, principles from psychomotor physiotherapy were applied [
34]. The purpose of the exercises was to improve balance, posture and breathing, and to provide participants with techniques to increase body awareness and their ability to relax. In addition, the course emphasised group discussions and sharing of experiences among participants.
The self-management course was delivered as a weekly 2.5-h group session during the daytime (12.30 pm- 15.00 pm) for six weeks, for a total of 15 h. Two dedicated employees with professional backgrounds as physiotherapists experienced in working with behavioural changes, self-management and chronic pain facilitated the self-management course. One of the physiotherapists involved in developing and delivering the course was educated within psychomotor physiotherapy and had extensive experience from a multidisciplinary hospital pain clinic.
The guidelines regarding how to carry out the self-management course are available through the published protocol [
27].
Primary outcome
The chronic pain self-management course was hypothesised to strengthen the participants’ engagement in and knowledge of available health resources, which consequently was expected to lead to a higher level of patient activation. Thus, patient activation was chosen as the main outcome [
27], and was measured using the Patient Activation Measure, PAM-13 [
39]. The PAM-13 contains 13 statements to which the participants indicate their level of agreement on a four-point Likert scale, from 1 = ‘strongly disagree’ to 4 = ‘strongly agree’ with an additional ‘not applicable’ option. The raw score is transformed to a total score ranging from 0 to 100 [
40], with higher scores indicating that the individual is more activated to adopt and to maintain healthy behaviours and self-management strategies for their illness, even under stress [
15]. When participants answered that a statement was not applicable to them, the data was treated as missing. A total score was generated if participants answered at least 10 of the 13 statements [
40].
The PAM-13 scores can be divided into four levels of activation [
39]. Level 1 (score 0.0–47.0) indicates that a person may not yet understand that the patient’s role is important. Level 2 (score 47.1–55.1) indicates a lack of confidence and knowledge to take action. Level 3 (score 55.2–72.4) indicates that a person is beginning to engage in recommended health behaviours, whereas level 4 (score 72.5–100.0) indicates that a person is proactive regarding their health and engages in several recommended health behaviours [
41,
42]. Patient activation levels have been used in studies as cut-off values to stratify participants and to investigate the effects of interventions in accordance with the different levels [
41,
43,
44].
The PAM-13 is considered useful for assessing patient engagement in the management of chronic illness, including chronic pain, and for assessing sensitivity to changes in several groups and populations [
15,
39,
45]. The measure has been translated into Norwegian (Cronbach’s alpha 0.91) [
46]. Studies have shown that the Norwegian version of the measure is valid and reliable when tested for patient education interventions in a Norwegian hospital [
46], in a RCT of hospital out-patient self-management education for patients with polyarthritis (Cronbach’s alpha 0.80) [
47] and in a RCT of mental health treatment (Cronbach’s alpha = 0.87) [
43]. Relevant for this study, the PAM-13 has been used in the above-mentioned study on polyarthritis patient education [
47] and in an evaluation study of self-management interventions, including persons with chronic pain [
45]. In the current study, the Cronbach’s alpha at the baseline was 0.75.
Secondary outcomes
Several secondary outcomes were chosen in consideration of the recommendations from the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT) [
48,
49], systematic reviews on self-management [
17,
23,
24,
50] and findings from studies on persons with chronic pain and self-management (e.g., [
47,
51,
52]).
Experiencing chronic pain was the main inclusion criteria. Therefore, pain severity and pain interference were assessed using the Brief Pain Inventory (BPI) [
53].The instrument includes four questions related to severity and seven questions regarding interference where all items are rated on 0–10 scales, with 10 being pain as bad as one can imagine, or pain that interferes completely. In addition, the instrument includes one item that asks about the percentage of pain relief with the use of analgesics [
53]. The instrument has been translated to Norwegian (Cronbach’s alpha 0.87 for pain severity and 0.92 for the interference scale) [
54] and has been used in Norwegian studies of a multidisciplinary pain management programme [
55] and among patients with osteoarthritis (Cronbach’s alpha > 0.80) [
56]. In the current study, the Cronbach’s alpha at the baseline was 0.81 for pain severity and 0.86 for pain interference.
The experience of pain during the previous week was assessed using a one-item 100 mm Visual Analogue Scale (VAS) [
57]. The participants were asked to draw a vertical mark on the 100 mm line indicating their average pain during the previous week. The scale’s anchoring points were no pain (0) and intolerable pain (100). The VAS has been validated and found to be reliable in the assessment of chronic pain [
57].
Psychological distress is commonly reported among individuals suffering chronic pain [
2,
5], which makes this a relevant domain to assess. Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS), which consists of 14 items divided into two subscales, with seven items each for depression and anxiety [
58]. Each item is rated from not experiencing symptoms (0) to experiencing symptoms nearly all the time (3). This instrument has shown good validity and reliability for patients with musculoskeletal pain (Cronbach’s alpha for the anxiety subscale 0.83 and for the depression subscale 0.84) [
59] as well as in a Norwegian large population study (The Nord-Trøndelag Health Study, HUNT) (Cronbach’s alpha 0.80 for the anxiety subscale and 0.76 for the depression subscale) [
60]. In the current study, the Cronbach’s alpha at the baseline was 0.73 for the depression subscale and 0.76 for the anxiety subscale.
Self-efficacy concerns the confidence people have that they can successfully execute a course of action to accomplish a desired outcome in a given situation [
61]. This was measured using the Pain Self-Efficacy Questionnaire (PSEQ), which specifically assesses beliefs regarding one’s ability to accomplish various activities, despite the pain [
62]. The PSEQ includes 10 items that respondents rate on a scale from 0 to 6 regarding how confident they are that they can perform an activity at present despite pain, where 6 equals completely confident [
62]. The questionnaire has been tested in large samples of heterogeneous patients with chronic pain (Cronbach’s alpha 0.92) [
62] and has been translated and validated in several languages and populations [
63]. It has previously been translated for use in a Norwegian study (Cronbach’s alpha not reported) [
64]. In the current study, the Cronbach’s alpha at the baseline was 0.84.
A sense of coherence has been suggested to be an important coping mechanism and strategy for people with chronic musculoskeletal pain [
65] and is related to salutogenesis, which is fundamental to the activities at the HLC [
28]. Therefore, this was included as an aspect to assess by using the Sense of Coherence (SOC) scale [
66]. The 13 items of the scale measure the perception of the environments’ comprehensibility, manageability and meaningfulness, with each item scored using a range from 1 to 7. The score of each item is summed to a total score, with a range from 13 to 91. The higher the score, the stronger the sense of coherence. The SOC scale has been found to be a reliable, valid and cross-culturally applicable instrument that measures how people manage stressful situations and stay well (Cronbach’s alpha in 127 studies 0.70–0.92) [
66]. The Norwegian version of the SOC-13 has been used in a study of patients with long-term musculoskeletal pain (Cronbach’s alpha not reported) [
67] and in a study on multidisciplinary rehabilitation for patients with chronic musculoskeletal pain (Cronbach’s alpha 0.83) [
68]. In the current study, the Cronbach’s alpha at the baseline was 0.87.
Living with chronic pain often affects people’s health-related quality of life [
69]. The generic health-related quality of life was assessed using the EuroQoL (EQ-5D-5 L) [
70]. This instrument provides five levels to answer each of the dimensions mobility, self-care, usual activities, pain/ discomfort, and anxiety/ depression [
71]. The descriptive score was converted to an index value of health status using the Danish value set, giving a range from 1 (perfect health) to 0 (death) [
70,
71]. The instrument has been validated in similar populations [
72], as well as in a Norwegian context (Cronbach’s alpha 0.69) [
73]. In the current study, the Cronbach’s alpha at the baseline was 0.55.
In addition to the assessment of health-related quality of life, the participants’ experiences related to global well-being during the previous month was assessed using the Arizona Integrative Outcomes Scale (AIOS) by means of a one-item 100 mm long VAS [
74]. The question asked was ‘Reflect on your sense of well-being during the last month. Take into account your physical, mental, emotional, social and spiritual condition, and mark the line for your summarised overall sense of wellbeing’. The scale’s anchoring points were ‘worst you have ever been’ (0) and ‘best you have ever been’ (100) [
74]. The AIOS has been found to be a valid measure for assessing well-being [
74], and it has previously been used in a Norwegian study including persons that experience chronic pain [
47].
In addition, the participants’ global self-rated health was assessed using the question ‘By and large, would you say that your health is:’ followed by the options ‘poor’, ‘not so good, ‘good’, ‘very good’ and ‘excellent’. This question is similar to a question asked in a major population study in Norway (HUNT) [
75].
Because chronic pain can affect physical functioning and physical exercise has been shown to have beneficial effects on chronic pain [
36,
37], two questions were included related to physical functioning. First, physical activity was assessed based on the average number of times participants exercised per week using the question: ‘How often do you exercise on average? (exercise refers to walking, skiing, swimming and working out/ sports)’ followed by the options ‘never’, ‘less than once a week’, ‘once a week’, ‘2-3 times a week’ and ‘nearly every day’. This question was used in a major population study in Norway [
75] and in investigations of associations between exercise and chronic pain [
76]. Second, as an objective measure of physical ability, the 30-s Chair to Stand Test was used to measure lower body strength [
77]. Participants were told to sit on a chair with their hands on the opposite shoulder and feet flat on the floor. On a signal, they rose to a full stand and returned to a fully seated position, without using their arms. The score is the total number of unassisted stands during the 30-s time frame. The measure has shown to be valid and have good test-retest reliability in older adults [
77] and has been used in studies including patients with fibromyalgia [
78], knee and hip pain [
79] and arthritis [
80].
Statistics
All the outcome measures were found to be approximately normally distributed. The confidence level was set at 95%, and the predefined cut-off level for statistical significance was set at p ≤ 0.05. No interim analysis was performed.
The effect of the intervention was assessed using intention to treat (ITT) and per-protocol (PP) analyses. The PP criterion was that participants had been present for a minimum of three of the six sessions. The PP analyses provided similar findings and did not change any conclusions regarding the interventions. Thus, they are not further discussed.
The between group differences are analysed only after 12 months, and the within-group changes after six and 12 months.
Analyses of the primary and secondary outcomes were performed using a linear mixed model. The participants’ identification number (ID) was specified as a random effect to allow participants to begin at different levels of the outcome in question. The effects of intervention and time were specified as fixed with the following values: 1) ‘baseline’, 2) ‘control 6 months’, 3) ‘intervention 6 months’, 4) ‘control 12 months’ and 5) ‘intervention 12 months’, acknowledging that differences between groups at the baseline were due to chance. The missing data were managed using the mixed linear model in which all available data are used. The regression assumptions were checked [
81], resulting in satisfactory values. The analyses of the estimated changes from the baseline to six months and from the baseline to 12 months were performed separately.
Changes in work status and pain medication (categorical data) since the last assessment were analysed using Pearson’s Chi-Square test or Fisher’s exact test. The frequency of healthcare utilisation during the previous three months was compared between the groups using t tests.
One exploratory post-hoc subgroup analysis was performed to investigate whether changes in the primary outcome (PAM-13) varied according to patient activation levels at baseline. The reason for performing this analysis was a discussion after the study began regarding which groups of participants the course could possibly be best suited for, partly due to considerations made after a qualitative study about expectations towards participation with a selection of the participants in the RCT [
82]. Because there were few participants at the lowest patient activation levels, patient activation levels 1 and 2 were combined, creating three subgroups. Distribution according to the different PAM-levels at baseline is displayed in Table
1. A linear regression analysis was performed to test for an interaction between the baseline patient activation level and allocation. The dependent variable was the change in PAM-13 from the baseline to twelve months. The independent variables were the PAM-13 level at the baseline and allocation (intervention or control group).
Table 1
Baseline characteristics of participants
Characteristics | ALL (N = 121) | INTV (n = 60) | CTRL (n = 61) |
Female, n (%) | 106 (87.6%) | 53 (88.3%) | 53 (86.9%) |
Age years, mean (SD), | 52.7 (11.7) | 52.1 (11.4) | 53.3 (12.1) |
(range) | (23–74) | (27–71) | (23–74) |
Living with someone, n (%) | 86 (71.1%) | 43 (71.7%) | 43 (70.5%) |
Highest level of education, n (%) |
lower secondary school or less | 8 (6.6%) | 4 (6.7%) | 4 (6.6%) |
upper secondary school | 56 (46.3%) | 28 (46.7%) | 28 (45.9%) |
higher education (college or university) | 57 (47.1%) | 28 (46.7%) | 29 (47.5%) |
Main reason for pain, n (%): |
musculoskeletal diseases, ICPC-2 chapter L | 93 (76.9%) | 46 (76.7%) | 47 (77.0%) |
neuro system diseases, ICPC-2 chapter N | 16 (13.2%) | 10 (16.7%) | 6 (9.8%) |
general and unspecified, ICPC-2 chapter A | 12 (9.9%) | 4 (6.7%) | 8 (13.1%) |
Pain duration, n (%) |
7–11 months | 2 (1.7%) | 2 (3.3%) | 0 (0%) |
1–5 years | 24 (19.8%) | 12 (20.0%) | 12 (19.7%) |
6–9 years | 19 (15.7%) | 11 (18.3%) | 8 (13.1%) |
10 years or more | 76 (62.8%) | 35 (58.3%) | 41 (67.2%) |
More than one chronic condition, n (%) | 76 (62.8%) | 32 (53.3%) | 44 (72.1%) |
Work status, n (%) |
working, full or part time | 31 (25.6%) | 13 (21.7%) | 18 (29.5%) |
disability pension, full or graded | 56 (46.3%) | 33 (55%) | 23 (37.7%) |
sick leave, full or graded | 20 (16.5%) | 8 (13.3%) | 12 (19.7%) |
retired | 14 (11.6%) | 6 (10.0%) | 8 (13.1%) |
Pain medication, n (%): |
prescription-only | 51 (42.1%) | 23 (38.3%) | 28 (45.9%) |
without prescription | 41 (33.9%) | 19 (31.7%) | 22 (36.1%) |
do not use pain medication | 29 (24.0%) | 18 (30.0%) | 11 (18.0%) |
Healthcare utilization, last 3 months: |
visits general practitioner, mean (SD) | 1.9 (1.9) | 1.6 (1.7) | 2.1 (2.0) |
visits physiotherapist, mean (SD) | 4.8 (6.3) | 4.5 (5.9) | 5.1 (6.8) |
stays rehabilitation centre, mean (SD) | 0.07 (0.3) | 0.1 (0.3) | 0.05 (0.2) |
visits hospital outpatient clinic, mean (SD) | 0.6 (1.1) | 0.5 (0.9) | 0.6 (1.3) |
admission hospital, mean (SD) | 0.1 (0.7) | 0.2 (1.0) | 0.02 (0.1) |
number of days, mean (SD), (range) | 0.1 (0.8) (0–8) | 0.2 (1.2) (0–8) | 0.02 (0.1) (0–1) |
PAM-13 level at baseline | N = 119 | n = 58 | n = 61 |
Level 1 | 16 (13.4%) | 9 (15.5%) | 7 (11.5%) |
Level 2 | 12 (10.1%) | 3 (5.2%) | 9 (14.8%) |
Level 3 | 61 (51.3%) | 32 (55.2%) | 29 (47.5%) |
Level 4 | 30 (25.2%) | 14 (24.1%) | 16 (26.2%) |
The first author performed the analyses, which were overseen and discussed with the co-authors and a statistician. All the analyses were performed using Stata Statistical Software (Release 14; StataCorp LP, 2014, College Station, TX, USA).